Benitec Biopharma (BNTC) Net Cash Flow (2019 - 2025)

Benitec Biopharma has reported Net Cash Flow over the past 7 years, most recently at $94.5 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $94.5 million for Q4 2025, up 830.28% from a year ago — trailing twelve months through Dec 2025 was $110.8 million (up 92.26% YoY), and the annual figure for FY2025 was $46.9 million, down 3.24%.
  • Net Cash Flow reached $94.5 million in Q4 2025 per BNTC's latest filing, up from -$3.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $94.5 million in Q4 2025 and bottomed at -$6.4 million in Q1 2024.
  • Median Net Cash Flow over the past 5 years was -$3.3 million (2021), compared with a mean of $8.7 million.
  • The largest annual shift saw Net Cash Flow plummeted 163.37% in 2022 before it surged 997.88% in 2024.
  • Over 5 years, Net Cash Flow stood at -$3.3 million in 2021, then crashed by 76.25% to -$5.9 million in 2022, then rose by 10.15% to -$5.3 million in 2023, then skyrocketed by 293.02% to $10.2 million in 2024, then soared by 830.28% to $94.5 million in 2025.
  • Business Quant data shows Net Cash Flow for BNTC at $94.5 million in Q4 2025, -$3.4 million in Q3 2025, and -$5.7 million in Q2 2025.